Dermsquared

AI-powered search

On-Demand CME Videos

FC24: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch: An Online Activity

About

Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch: An Online Activity

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals, Inc.

Availability

In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:

Release Date:

December 6, 2024

Expiration Date:

December 6, 2025

Learning Objectives

At the completion of this activity, participants should be better able to:

Describe how systemic therapies target the itch pathway in prurigo nodularis (PN) and atopic dermatitis (AD)
Review the role of current and emerging systemic therapies that target itch associated with PN and AD
Discuss patient-centered strategies for integrating new and emerging therapies for itch in PN and AD into clinical care

Intended Audience

This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.

Faculty

Shawn Kwatra, MD

Joseph W. Burnett Professor and Chairman
Department of Dermatology
University of Maryland School of Medicine
Baltimore, MD

Tejesh Patel, MD, FAAD

Chair, Professor

The University of Tennessee Health Science Center

Memphis, Tennessee

Mona Shahriari, MD

Dermatologist, Yale University School of Medicine
Central CT Dermatology
Cromwell, CT

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

Disclosures are as follows:

Shawn Kwatra, MD

Advisory Board: Abbvie, Amgen, Arcutis, Aslan Pharmaceuticals, Cara Therapeutics, Castle Biosciences, Celldex Therapeutics, Galderma, Incyte Corporation, Johnson & Johnson, Novartis, Leo, Regeneron, Sanofi Grant/Research Support: Galderma, Incyte, Pfizer, and Sanofi

Consultant: Abbvie, Amgen, Arcutis, Aslan Pharmaceuticals, Cara Therapeutics, Castle Biosciences, Celldex Therapeutics, Galderma, Incyte Corporation, Johnson & Johnson, Novartis, Leo, Regeneron, Sanofi

Tejesh Patel, MD, FAAD

No relevant financial relationships with any Ineligible Company in the past 24 months.

Mona Shahriari, MD

Grant/Research Support: AbbVie, Dermira, Cara, Dermavant, Novartis, Union

Consultant: Abbvie, BMS, Dermavant, Leo, Lilly, Sanofi, Regeneron, UCB

Speakers’ Bureau or Honoraria: Abbvie, BMS, Lilly, Leo, Janssen, Dermavant

The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.